Tumor Blood Testing Market Seen Reaching $11.13B by 2030

The tumor blood testing market is projected to grow from $5.98 billion in 2025 to $11.13 billion by 2030 as cancer rates rise and demand increases for less invasive diagnostics. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Tumor blood testing is gaining traction as a less invasive alternative to traditional tissue biopsies for cancer detection and monitoring. - Rising cancer incidence, including a larger survivor population, is expanding demand for earlier diagnosis and treatment tracking. - The market’s projected growth signals stronger adoption of liquid biopsy, companion diagnostics and AI-assisted genomic analysis across oncology care.

What happened: - The tumor blood testing market was valued at $5.98 billion in 2025 and is projected to reach $6.78 billion in 2026. - The market is forecast to grow at a 13.3% CAGR in 2026 and reach $11.13 billion by 2030 at a 13.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available. - A full market report is also available.

The details: - Tumor blood testing analyzes blood samples for cancer-specific biomarkers. - The technique focuses on genetic material released by tumors, including circulating tumor DNA, or ctDNA. - The method can support earlier cancer diagnosis, continuous disease monitoring and treatment planning. - Market growth is linked to the rising incidence of cancer, aging populations, poor diet, smoking, environmental pollution, limits of tissue biopsies and more genomic testing use. - Growth also reflects higher oncology research funding and stronger preference for non-invasive diagnostics. - The forecast period is expected to benefit from early screening programs, AI-powered genomic analysis, personalized medicine, broader use of companion diagnostics and use in clinical trials. - Key trends include wider liquid biopsy use, multi-cancer early detection, minimal residual disease monitoring, personalized oncology testing and improved biomarker sensitivity. - In May 2024, the National Cancer Institute said the U.S. had about 18.1 million cancer survivors as of January 2022 and projected that number would rise to 26 million by 2040.

Between the lines: - The market outlook suggests tumor blood testing is moving from a niche diagnostic tool toward a broader role in routine oncology workflows. - Faster growth in Asia-Pacific likely reflects expanding healthcare access, diagnostic adoption and cancer-testing demand across the region. - The rise in survivors adds another layer of demand because long-term monitoring can require repeated testing without invasive procedures.

What's next: - The market is likely to keep expanding as liquid biopsy platforms improve and multi-cancer testing becomes more common. - More clinical trial use and companion diagnostic adoption could deepen the role of tumor blood testing in treatment selection and follow-up care. - The Business Research Company said the 2026 edition of its reports adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics and updated trend analysis. - The company also provided more information on its LinkedIn page.